Tag: BTXA

Korean botulinum toxin companies are experiencing delays in entering the Chinese market due to increased regulatory scrutiny and growing competition. I-Maker Technology and Daewoong Pharmaceutical have both postponed their commercialization schedules to 2025. The market sees an influx of new products, intensifying competition and price pressures within the sector, despite projected growth by Goldman Sachs…